Global Biologics Market Is Estimated To Witness High Growth Owing To Rising Demand for Targeted Therapies and Increasing Investment in Research and Development


The Biologics Market is estimated to be valued at US$ 401.96 billion in 2023 and is expected to exhibit a CAGR of 9.3% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

The Biologics Market refers to the production and sale of pharmaceutical products that are derived from living organisms or contain components of living organisms. These products include vaccines, insulin, hormones, antibodies, gene therapy, and cell-based therapies. Biologics have revolutionized the field of medicine by providing targeted therapies that specifically treat various diseases and conditions. They offer improved efficacy, reduced side effects, and personalized treatment options for patients. The market for biologics is driven by the growing demand for targeted therapies and the increasing investment in research and development in the pharmaceutical industry.

Market Dynamics:

The growth of the biologics market is primarily driven by two key factors. Firstly, the rising demand for targeted therapies has led to an increased adoption of biologics. These therapies are designed to specifically target and attack disease cells while minimizing damage to healthy cells, resulting in improved treatment outcomes. Secondly, there is a significant investment in research and development within the pharmaceutical industry to develop innovative biologic products. This investment is driven by the potential for high returns on investment due to the growing demand for biologics and the increasing prevalence of chronic diseases. These two factors combined are expected to propel the growth of the biologics market over the forecast period.

SWOT Analysis:

The biologics market is expected to grow at a significant CAGR of 9.3% during the forecast period of 2023-2030. This growth is fueled by the increasing demand for biologics due to their effectiveness in treating various diseases, such as cancer and autoimmune disorders. Additionally, advancements in biotechnology and research & development activities are driving the growth of the market.

One weakness of the biologics market is the high cost associated with the development and production of biologics. This cost is mainly due to the complex manufacturing process and the need for advanced infrastructure. Furthermore, strict regulatory requirements and lengthy approval processes pose challenges to market entry for new players.

There are several opportunities in the biologics market. Firstly, the increasing prevalence of chronic diseases such as cancer and diabetes creates a growing demand for effective biologic therapies. Additionally, the expansion of biologics into emerging markets presents a significant opportunity for market growth, as these regions have a large population in need of advanced healthcare solutions.

The biologics market faces threats from the rising competition from biosimilar products. Biosimilars are generic versions of biologics that are produced after the expiration of the patent. These biosimilars are usually priced lower, which can negatively impact the market share of original biologics. Additionally, stringent regulations and quality requirements pose a threat to market growth as they can hinder the timely launch of new biologics.

Key Takeaways:

The Global Biologics Market Size is expected to witness high growth, exhibiting a CAGR of 9.3% over the forecast period, due to increasing demand for effective biologic therapies. North America is expected to be the fastest-growing and dominating region, driven by the presence of key players and high healthcare expenditure. Some of the key players operating in the biologics market include Novartis AG, AstraZeneca PLC, Bayer AG, Sanofi SA, Pfizer Inc., Merck & Co., Johnson and Johnson, GlaxoSmithKline PLC, Amgen Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Eli Lilly and Company, and AGC Biologics.



1.  Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it